Novel Therapies for Pulmonary Arterial Hypertension
PH Therapeutics Ltd is a new business that intends to develop novel antibody therapies to treat the orphan disease Pulmonary Arterial Hypertension (PAH). The goal is to develop these new therapies to the clinic and to bring benefit to patients suffering from this rare and debilitating disease.
The Market and the Unmet Need
Pulmonary arterial hypertension is a condition where there is high blood pressure in the arteries that supply the lungs. In patients with pulmonary arterial hypertension, there is a thickening of the muscles in the walls of the arteries and a narrowing of the arteries in the lungs, making it harder for blood to flow to the lungs. Pulmonary arterial hypertension is a long-term debilitating and life-threatening condition that shortens patients’ life expectancy because it may lead to heart failure and difficulty breathing. PAH affects around 2 in 10,000 people in the European Union and is classed as an orphan disease.
Current therapies attempt to alleviate the symptoms of this disease through relaxing the vessels. Through the work of Dr Allan Lawrie at the University of Sheffield, PH Therapeutics is developing novel antibody therapies that aim to reverse the progression of pulmonary arterial hypertension leading to improved treatments for patients.